Cutaneous T-Cell Lymphoma clinical trials at UC Irvine
2 in progress, 0 open to eligible people
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Sorry, in progress, not accepting new patients
The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by objective response rate (ORR). A lead-in dose-finding part was used to determine dose level 9 microgram per kilogram (mcg/kg) E7777 that is being used to test efficacy and safety.
Orange, California and other locations
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Sorry, not currently recruiting here
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.
Irvine, California and other locations
Last updated: